Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
Financials
Financial year 2025
IQVIA Cancer Research from Zaventem, company number BE0763914095, closed financial year 2025 with a result of € 38,859 after tax. For that financial year IQVIA Cancer Research recorded a gross margin of € 50,247 and equity of € -269,667. Compared with financial year 2024, the result moved from € 2,686 to € 38,859. Profitable, and profit is growing. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 1, 2026.
€ -269,667
▲ € 38,859 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 38,859
▲ € 36,173 vs 2024
Profit after tax over the fiscal year.
€ 49,130
▼ 90% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -269,767.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 14,050
▼ 95% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -112,966 | € -85,978 | € 18,152 | € 50,247 | ▲ 177% |
| Profit after taxes | € -117,893 | € -102,166 | € 2,686 | € 38,859 | ▲ € 36,173 |
| Equity | € -209,046 | € -311,212 | € -308,526 | € -269,667 | ▲ € 38,859 |
| Total debts | € 510,463 | € 552,460 | € 943,970 | € 1,341,148 | ▲ 42% |
| Cash | € 288,494 | € 236,356 | € 484,181 | € 49,130 | ▼ 90% |
| Retained profit | € -209,146 | € -311,312 | € -308,626 | € -269,767 | ▲ € 38,859 |
| Balance sheet total | € 301,417 | € 241,248 | € 635,445 | € 1,071,481 | ▲ 69% |
By gross margin, IQVIA Cancer Research ranks 57th of 90 companies with main activity “Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied” in Flemish Brabant that publish figures (fiscal year 2025).
Key figures of IQVIA Cancer Research, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about IQVIA Cancer Research the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to IQVIA Cancer Research?
What happened at IQVIA Cancer Research in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 38,859 (▲ € 36,173 vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- Robert Kotchie became a director. NBB
In short
From € 117,893 loss in 2022 to € 38,859 profit in 2025.
Best year ever: 2025, with € 38,859 profit.
Management
Behind IQVIA Cancer Research is Robert Kotchie. The shares are held by IQVIA LTD (100%).
Directors
According to the 2025 annual accounts
Robert Kotchie
Gedelegeerd bestuurder
since 2021
Shareholders
IQVIA LTD
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Da Vincilaan 7
1930 Zaventem
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 7 companies are registered at this address.
All companies at this address →IQVIA Solutions Belgium
€ 33.1 million revenue · 2025
TAKEDA BELGIUM
€ 207.4 million revenue · 2026
IQVIA RDS & INTEGRATED SERVICES BELGIUM
€ 45.6 million revenue · 2025
IM ASSOCIATES
€ 3.1 million gross margin · 2025
Orifarm Healthcare
€ 31.3 million revenue · 2025
+2 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Flemish Brabant
Same main activity (Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied), 135 active companies in Flemish Brabant, largest first.
Interuniversitair Micro-Electronica Centrum
€ 804.3 million revenue · 2025 · Leuven
€ 189.5 million revenue · 2025 · Tienen
Laboratoire belge de l'Industrie Electrique
€ 106.1 million revenue · 2025 · Linkebeek
€ 62.7 million revenue · 2025 · Vilvoorde
€ 41.8 million revenue · 2025 · Zaventem
€ 41.3 million revenue · 2025 · Leuven
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- IQVIA LTD.(oprichter) 100%
Details
- Company number
- 0763.914.095
- VAT number
- BE 0763.914.095
- Registered office
- Da Vincilaan 7, 1930 Zaventem
- Names & denominations
- IQVIA Cancer Research
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 February 2021
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied